Recently it has been also been demonstrated that a tumor vaccine called fibroblast activation protein-α (FAP) gene-engineered tumor cell-derived exosome-like nanovesicles (eNVs-FAP) can target both tumor parenchyma and the stromal cells (CAFs) which contribute to tumor growth, metastasis, immunosuppression, and drug resistance [142]. This evidence concerns the gene FAP and neoplasm.